Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

To quote Mark Twain, "The rumors of my

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stoneroad Member Profile
Member Level 
Followed By 25
Posts 2,824
Boards Moderated 0
Alias Born 02/12/09
160x600 placeholder
ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK "InvestorsHub NewsWire" - 10/14/2014 6:00:00 AM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "Marketwired" - 6/10/2014 4:00:00 PM
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab & I... "Marketwired" - 4/23/2014 7:30:00 AM
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Thera... "PR Newswire (US)" - 4/10/2014 12:28:00 PM
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor & Immune... "Marketwired" - 4/9/2014 11:00:00 AM
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma "PR Newswire (US)" - 4/8/2014 1:15:00 PM
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiati... "Marketwired" - 4/7/2014 8:00:00 AM
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting "Marketwired" - 4/1/2014 4:00:00 PM
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Pe... "Marketwired" - 3/14/2014 8:00:00 AM
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-... "Marketwired" - 3/13/2014 8:00:00 AM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "Marketwired" - 3/11/2014 4:10:00 PM
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome ... "Marketwired" - 3/11/2014 8:00:00 AM
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments "Marketwired" - 3/7/2014 8:00:00 AM
Pre-Market Review of Top Gainers: Canadian Solar, Qihoo 360 Technology, Peregrine Pharma, Renren, and UTi Worldwide "PR Newswire (US)" - 3/5/2014 10:40:00 AM
Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Sympo... "Marketwired" - 3/4/2014 4:00:00 PM
Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014 Financial Results Before Market Open on March 7, 2014 "Marketwired" - 2/27/2014 4:00:00 PM
Peregrine Pharmaceuticals Announces Partial Exercise of Overallotment Option in Connection With Preferred Stock Offering "Marketwired" - 2/27/2014 12:18:24 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/19/2014 4:11:21 PM
Peregrine Pharmaceuticals Announces Upcoming Events "Marketwired" - 2/19/2014 4:00:00 PM
Peregrine Pharmaceuticals Announces Closing of Preferred Stock Offering "Marketwired" - 2/19/2014 10:15:17 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/12/2014 5:23:36 PM
Securities Registration (section 12(b)) (8-a12b) "Edgar (US Regulatory)" - 2/12/2014 5:20:59 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 2/12/2014 5:01:05 PM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) "Edgar (US Regulatory)" - 2/11/2014 8:10:52 AM
Peregrine Pharmaceuticals Prices Offering of Its Series E Preferred Stock "Marketwired" - 2/11/2014 8:00:00 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist